Posted by Michael Wonder on 15 Nov 2019
Valeo Pharma announces filing of a new drug submission for low molecular weight heparin in Canada
14 November 2019 - Valeo Pharma announced today that the new drug submission filed for a low molecular weight heparin biosimilar has been accepted for review by Health Canada.
Low molecular weight heparins (LMWHs) are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism. Total Canadian sales of LMWHs exceeded $200M in 2018.
There are currently no LMWH biosimilars approved by Health Canada.
